ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,096 GBX | -0.12% |
|
-1.80% | +14.11% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.11% | 239B | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B | |
| -0.90% | 162B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study
